Sector pending / Pharmaceutical PreparationsUpdated 2026-05-10 22:07 UTC

BCBA/AZN stock hub

BCBA/AZN has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BCBA/AZNis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

392.8T

Buenos Aires Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

BCBA/AZN

In the news

Latest news · BCBA/AZN

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E17.1

P25 n/aP50 n/aP75 n/a

Trailing P/E27.4

P25 n/aP50 n/aP75 n/a

ROE23.5

P25 n/aP50 n/aP75 n/a

ROIC16.4

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BCBA/AZN market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

222

Groups with data

Currency

USD

Showing 222 of 222 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United Kingdom
Country code	AR
Employees	96,100
Employees Change	4,400%
Employees Change Percent	4.89
Enterprise value	ARS 430.7T
Exchange	Buenos Aires Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Pharmaceutical Preparations
Last refreshed	2026-05-10
Market cap	ARS 392.8T
Price	ARS 67,750
Price currency	ARS
Rev Per Employee	868,858,548.54x
Sic	2834
Symbol	bcba/AZN
Website	https://www.astrazeneca.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.65%
EV Earnings	30.01x
EV/EBIT	20.1x
EV/EBITDA	14.7x
EV/FCF	27.61x
EV/Sales	4.96x
FCF yield	3.97%
Forward P/E	17.11x
P/B ratio	6x
P/E ratio	27.37x
P/S ratio	4.7x
PE Ratio10 Y	84.81x
PE Ratio3 Y	31.68x
PE Ratio5 Y	131.57x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	24.69%
EBITDA Margin	33.08%
FCF margin	18.68%
Gross margin	81.51%
Gross Profit	ARS 68.1T
Gross Profit Growth	8.69%
Gross Profit Growth Q	11.17%
Gross Profit Growth3 Y	10.18%
Gross Profit Growth5 Y	17.61%
Net Income	ARS 14.4T
Net Income Growth	33.67%
Net Income Growth Q	5.62%
Net Income Growth3 Y	30.22%
Net Income Growth5 Y	21.17%
Pretax Margin	21.37%
Profit Margin	17.19%
Profit Per Employee	ARS 149.4M
ROA	8.47
Roa5y	5.95
ROCE	18.32
ROE	23.48
Roe5y	13.03
ROIC	16.4
Roic5y	13.29

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	67.71%
Cagr3y	60.4%
Cagr5y	75.73%
Div CAGR10	43.39%
Div CAGR3	106.6%
Div CAGR5	105.6%
EPS Growth	33.61
EPS Growth Q	5.35
EPS Growth3 Y	30.03
EPS Growth5 Y	16.98
FCF Growth	1.26%
FCF Growth Q	-14.37%
FCF Growth3 Y	9.55%
FCF Growth5 Y	15.06%
OCF Growth	8.66%
OCF Growth Q	-9.53%
OCF Growth10 Y	11.98%
OCF Growth3 Y	13.57%
OCF Growth5 Y	16.62%
Revenue Growth	9.93x
Revenue Growth Q	12.51x
Revenue Growth3 Y	11.3x
Revenue Growth5 Y	16.99x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	ARS 0.55
Assets	ARS 157.5T
Cash	ARS 10.6T
Current Assets	ARS 41.4T
Current Liabilities	ARS 45.6T
Debt	ARS 47T
Debt EBITDA	ARS 1.67
Debt Equity	ARS 0.72
Debt FCF	ARS 3.01
Equity	ARS 65.5T
Interest Coverage	10.59
Liabilities	ARS 92.1T
Long Term Assets	ARS 116.1T
Long Term Liabilities	ARS 46.5T
Net Cash	ARS -36.4T
Net Cash By Market Cap	ARS -9.27
Net Debt EBITDA	ARS 1.32
Net Debt Equity	ARS 0.56
Net Debt FCF	ARS 2.33
Tangible Book Value	ARS -14.9T
Tangible Book Value Per Share	ARS -9,605

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.91
Inventory Turnover	1.8
Net Working Capital	ARS -3.6T
Quick ratio	0.7
Working Capital	ARS -4.1T
Working Capital Turnover	ARS -28,080

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.08%
Dividend Growth	40.91%
Dividend Growth Years	4%
Dividend per share	ARS 986
Dividend Years	5
Dividend Yield	1.46%
Ex Div Date	2026-02-20
Last Dividend	ARS 683
Payout Frequency	Semi-Annual
Payout Ratio	46.07%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	67.65%
200-day SMA	64,327.4
3Y total return	312.84%
50-day SMA	71,785.5
50-day SMA vs 200-day SMA	50over200
5Y total return	1,575.18%
All Time High	79,800
All Time High Change	-15.1%
All Time High Date	2025-11-27
All Time Low	3,038
All Time Low Change	2,130.09%
All Time Low Date	2020-09-04
ATR	1,420.4
Ch YTD	-3.97
High	68,225
High52	79,800
High52 Date	2025-11-27
High52ch	-15.1%
Low	67,550
Low52	38,200
Low52 Date	2025-06-19
Low52ch	77.36%
Ma50ch	-5.62%
Price vs 200-day SMA	5.32%
RSI	38.12
RSI Monthly	65.07
RSI Weekly	49.35
Sharpe ratio	1.54x
Sortino ratio	2.6
Total Return	1.54%
Tr YTD	-2.99
Tr1m	-9.21%
Tr1w	-1.31%
Tr3m	-5.01%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	ARS 20.6T
Operating Income Growth	10.65
Operating Income Growth Q	17.2
Operating Income Growth3 Y	14.17
Operating Income Growth5 Y	29.99
Operating margin	24.69

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,543,451,508%
Net Borrowing	1,667,200,237,064
Shares Insiders	0.04%
Shares Institutions	68.53%
Shares Qo Q	-0.13%
Shares Yo Y	-0.08%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	ARS 15.1T
Average Volume	235.9x
Bv Per Share	42,215.1
CAPEX	ARS -4T
Ch1m	-9.21
Ch1w	-1.31
Ch1y	64.94
Ch3m	-5.97
Ch3y	295
Ch5y	1,487.8
Ch6m	8.49
Change	-0.18%
Change From Open	-0.37
Close	67,875
Days Gap	0.18
Depreciation Amortization	7,091,195,639,190
Dollar Volume	11,246,500
Earnings Date	2026-04-29
EBIT	ARS 20.6T
EBITDA	ARS 27.6T
EPS	ARS 9,173
F Score	7
FCF	ARS 15.6T
FCF EV Yield	3.62x
Financing CF	-6,313,517,609,000
Fiscal Year End	December
Founded	1,992
Goodwill	29,643,155,892,898
Graham Number	25080.21612
Graham Upside	-62.98
Income Tax	ARS 3.5T
Investing CF	-10,149,981,153,900
Is Primary Listing	0
Last Earnings Date	2026-04-29
Last Report Date	2026-03-31
Lynch Fair Value	ARS 52,418
Lynch Upside	-22.63
Ma150	68,677.8
Ma150ch	-1.35%
Ma20	71,322.5
Ma20ch	-5.01%
Net CF	3,187,152,105,900
Next Earnings Date	2026-07-27
Open	68,000
P FCF Ratio	25.17
P OCF Ratio	19.99
Payment Date	2026-03-23
Position In Range	29.63
Ppne	20,897,347,937,897
Price Date	2026-05-08
Price EBITDA	ARS 14.22
Relative Volume	0.7x
Revenue	83,497,306,514,300x
SBC By Revenue	0.61x
Share Based Comp	505,634,014,200
Tax By Revenue	4.17x
Tax Rate	19.52%
Tr6m	9.59%
Volume	166
Z Score	3.35

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

BCBA/AZN dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.5%

$986 annual per share

Payout ratio

+46.1%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+105.6%

4 consecutive years of growth

Total shareholder yield

+1.5%

Next ex-dividend date: 2026-02-20

Performance

BCBA/AZN stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BCBA/AZN?

Insider, institutional, and short-interest positioning.

Institutional ownership

+68.5%

Share of float held by funds and institutions

Insider ownership

+0.0%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.1%

Negative means the company is buying back shares.

Technical

BCBA/AZN momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

38.1

Neutral momentum band

Price vs 200-day MA

+5.3%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

1.54

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BCBA/AZN

Hub-level FAQ points readers to the deeper analysis pages.

What is the current bcba/AZN stock rating?

bcba/AZN is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full bcba/AZN analysis?

The full report lives at /stocks/bcba/AZN/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for bcba/AZN?

The latest report frames bcba/AZN around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the bcba/AZN page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.